NextCell Pharma

NextCell Pharma's mission is to develop and commercialize advanced, off-the-shelf cell therapies for autoimmune and inflammatory diseases, with a primary focus on Type 1 Diabetes. The company has established a unique and de-risked business model, generating foundational revenue from Scandinavia's largest private stem cell bank, Cellaviva, while advancing its lead candidate, ProTrans, through mid-stage clinical trials. Its strategy is built on a patented donor selection algorithm to ensure therapeutic potency and consistency, positioning it as a scalable player in the regenerative medicine field.

Proprietary platform based on umbilical cord-derived mesenchymal stromal cells (MSCs) selected for potency via a patented donor selection algorithm, enabling off-the-shelf, allogeneic cell therapies.

NextCell competes in the allogeneic MSC therapy space with numerous biotechs, differentiated by its selection algorithm and integrated biobank. In stem cell banking, it competes as Scandinavia's largest service. Its hybrid model provides a unique strategic position.